CONTROL BIONICS LIMITED — Capital/Financing Update 2021

Apr 6, 2021

==> picture [102 x 36] intentionally omitted <==

7 April 2021

ASX ANNOUNCEMENT

Reseller agreement with Numotion

Control Bionics (ASX:CBL), a global assistive technology company specialising in speech generating devices (SGDs) has entered into a reseller agreement with Numotion, a leading provider of Complex Rehab Technology (CRT) to offer the Control Bionics’ Trilogy product line in the US states of New Hampshire, Vermont, and New York.

Entering into the agreement with Numotion is in line with Control Bionics’ growth strategy to access the larger rehab market and reinforces its commitment to provide industry-leading solutions with access to all.

The reseller agreement is expected to increase market awareness and drive sales of the Control Bionics Trilogy Speech Generating Device as well as its best-in-class NeuroNode 3.0 sEMG (Electromyography) + Spatial sensor. Working with Numotion is expected to expand access to clients and clinicians who can benefit from Control Bionics’ customised Augmentative and Alternative Communication (AAC) solutions.

Control Bionics products have been introduced to help individuals dealing with a wide range of diagnoses, including ALS/MND, Spinal Muscular Atrophy (SMA), Cerebral Palsy (CP), traumatic brain injury (TBI), and spinal cord injury (SCI). The Trilogy product line is a best-inclass option in the wider category of AAC devices, offering a customizable solution that complements the individual’s abilities as their needs change over time alongside industryleading customer support.

"Control Bionics is passionate about helping clients find their 'voice' and regain control of their lives," explained Rob Wong, CEO of Control Bionics. "We're excited to be partnering with Numotion, an established company within the CRT space, to expand access to our lifechanging, multi-modal communication solutions throughout the Northeast."

"Adding Control Bionics' Trilogy product line to our offering of AAC devices allows us to better serve our clients looking for flexible access methods and multi-modal solutions,” said Amanda Whipple, Director of Augmentative Communication at Numotion. "Their unique approach to AAC devices matches our desire to consistently improve and expand our offerings with cutting edge technology, ultimately offering the greatest benefit to our customers in need."

Control Bionics products will be available to clients from this month, with clients able to make appointments now to begin the assessment process. Both Control Bionics and Numotion offer and support an extensive loan library of devices for clients and their clinicians wishing to trial this latest solution.

The material terms of the reseller agreement are as follows:

1. Numotion is appointed as a non-exclusive reseller of Control Bionics products ( Products ) in the states of New Hampshire, Vermont and New York (excluding New York City and Long Island).

Control Bionics Limited

Registered Office: Suite G.03, 171 Union Road, Surrey Hills, Vic., 3127 T: +61 3 9897 3576 W: www.controlbionics.com

ABN: 45 115 465 462

1. The reseller agreement will continue until terminated in accordance with the terms of the agreement. Either party may terminate the reseller agreement without cause upon providing 90 days written notice. The other termination clauses are the standard clauses expected in a commercial agreement of this kind.

2. Numotion will place orders for Products, the price being set out in the reseller agreement. Payment terms are 90 days from the date of placing the order.

3. There are no conditions precedent in the reseller agreement.

ABOUT NUMOTION

Numotion is the US’s largest and leading provider of products and services that provide mobility, health and personal independence. Its focus in Complex Rehab Technology (CRT), urological supplies, home accessibility, accessible vehicles and other assistive technology helps improve the lives of people with disabilities by enabling them to actively participate in everyday life. CRT is medically necessary, individually configured mobility products and services, including manual and power wheelchairs, designed to meet the unique medical and functional needs of individuals with significant disabilities and medical conditions to provide them with greater independence. Based in Brentwood, Tenn., Numotion has more than 150 locations across the country and serves more than 260,000 people. At Numotion, Mobility and Independence Start Here. For more information, please visit www.numotion.com.

This announcement was authorised by the CEO, Rob Wong.

Investors

Brett Crowley - Company Secretary brettcrowley@controlbionics.com

Business/Client Inquiries

Rob Wong - CEO robwong@controlbionics.com

USA

Tony Mackzum – Finance and Operations Director (USA) tonym@controlbionics.com

For further information visit the website: https://www.controlbionics.com/

About Control Bionics:

Control Bionics is a technology company which enables a disabled person to use their own neuroelectric signals, from their brain to a muscle, to control communication and movement through smartphones, tablets, computers and robotics, even when that muscle is not fully functional. The Company’s wireless wearable device, ‘ NeuroNode ’, is a world leader in electromyography (EMG), capturing and processing those neuroelectric signals into electronic commands to do everything they would normally do with a keyboard, mouse, joystick or touchscreen. The technology also enables a person to use their eyes to replace a mouse in controlling a cursor on a screen simply by looking where they want to cursor to move; and then to select anything under the cursor, using NeuroNode; providing fast, intuitive communication and control through text, text-to-speech, emails, phone-messaging, web surfing and robotics.

Control Bionics Limited

Registered Office: Suite G.03, 171 Union Road, Surrey Hills, Vic., 3127 T: +61 3 9897 3576 W: www.controlbionics.com

ABN: 45 115 465 462